Overview
RIVOX-AF study is a prospective, multicenter, randomized controlled study in which patients with AF are allocated to medication-app group or conventional treatment group. The App based feed-back algorithm will provide the patients with check taking drug or reminding of taking drug.
Eligibility
Inclusion Criteria:
- Male and female patients with atrial fibrillation with aged 19 years or older
- one or more of the following : heart failure, MI (3 month after onset), angina (3 month after PCI), hypertension or diabetes mellitus
- patients who already took or plan to take rivoxban
- patients who able to use smart phone
Exclusion Criteria:
- creatinine clearance <15ml/min
- moderate or severe mitral stenosis
- mitral valve operation history
- current alcohol abuse or alcohol abus history
- Not eligible for study due to legal or psychiatric problem
- enrolled other clinical study within 4 weeks
- declined to enroll the study